Stockholders' Equity (Tables) |
3 Months Ended | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Mar. 31, 2020 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Equity [Abstract] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Summary of Shareholders Equity Warrants Outstanding |
A summary of warrants outstanding as of March 31, 2020 and December 31, 2019 is presented below, all of which are fully vested:
* Weighted average exercise price for outstanding warrants is $0.62. ** Converted into approximately 1,453.0 thousand shares of commons stock. *** Weighted average exercise price for outstanding warrants is $0.58. |
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Schedule of Antidilutive Securities |
The following outstanding shares of potentially dilutive securities were excluded from the computation of diluted net loss per share attributable to common shareholders because including them would have been anti-dilutive as of March 31, 2020 and 2019:
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||